fashion -WSS

fashion

author：hotspot 2025-09-29 00:38:55 - browse：7539

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

WSS

Pfizer plans to depart BIO

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Why sickle cell disease is getting the first CRISPR treatment

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Even great ERs can’t make up for American health disparities

hotspot

fashion

explore

As demand for Covid shots wanes, Moderna seeks its next success

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Psychedelics group wrestles with new pharma identity

The real point of Kenneth Smith’s execution by nitrogen gas

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What causes an itch? Researchers may have solved the mystery

Cancer drug shortages should be causing more outrage

ARCH Venture Partners is raising $3 billion for a life sciences fund

hotspot

Time to name cancers by genetics, not organ of origin, expert says

Vertigo drug brings hope for rare neuron disorder, Niemann

Vertigo drug brings hope for rare neuron disorder, Niemann

What causes an itch? Researchers may have solved the mystery

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

SAMSHA loosens regulations on methadone treatment centers

entertainment

explore

entertainment

explore